Tuesday 30 April 2024
Internal Reference Number: FOI_6851
Date Request Received: 03/11/2022 00:00:00
Date Request Replied To: 02/12/2022 00:00:00
This response was sent via: By Email
Request Summary: Drugs in Ophthalmology and Metabolic diseases
Request Category: Private Individuals
| Question Number 1: For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab – Lucentis Ranibizumab – Ongavia | |
| Answer To Question 1: For the months from May to August 2022, how many patients received the following anti-VEGF treatment for any eye condition: Aflibercept 1404 Bevacizumab 30 Brolucizumab 0 Dexamethasone 13 Faricimab 0 Lucentis 325 Ongavia 0 | |
| Question Number 2: For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab – Lucentis Ranibizumab – Ongavia | |
| Answer To Question 2: Aflibercept 0 Bevacizumab 0 Brolucizumab 0 Dexamethasone 0 Faricimab 0 Lucentis <5 Ongavia 0 | |
| Question Number 3: How many patients have you treated in the last 12 months with the following drugs? Genotropin Humatrope Norditropin Nutropin Omnitrope Saizen Zomacton Any other Somatropin (please specify) | |
| Answer To Question 3: Genotropin 9 Humatrope 0 Norditropin <5 Nutropin 0 Omnitrope 0 Saizen 0 Zomacton 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
